For the Inventor, By the Inventor

Enter assignee name

Ab Science

USPTO Granted Patents = 29

% Expired Patents = 27.6

CIPO Patents = 2

EPO Patents = 18

Trademarks = 1

Forward Citations = 61

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

Alain Moussy (28 out of 28 patents)

Jean-Pierre Kinet (10 out of 15 patents)

Abdellah Benjahad (10 out of 11 patents)

4. Franck Sandrinelli (6 out of 6 patents)

5. Willy Picoul (6 out of 7 patents)

6. Didier Pez (6 out of 6 patents)

7. Jason Martin (6 out of 6 patents)

8. Emmanuel Chevenier (6 out of 6 patents)

9. Camille Georges Wermuth (6 out of 16 patents)

10. Bruno Giethlen (5 out of 23 patents)

11. Anne Lermet (4 out of 4 patents)

12. Marco Ciufolini (4 out of 4 patents)

13. Claire Schalon (3 out of 3 patents)

14. Philippe Reginault (3 out of 3 patents)

15. David Grierson (3 out of 18 patents)

Core Competencies:

Masitinib

Castrate-Resistant Prostate Cancer

Sickle Cell Disease

Tyrosine Kinase Inhibitors

Oxazole Derivatives

Protein Kinase Inhibitors

Amyotrophic Lateral Sclerosis

Mastocytosis

Severe Persistent Asthma

Multiple Sclerosis

Thiazole Compounds

29 patents: Sort by Forward Citations

1. 12648944 - Masitinib for the treatment of castrate-resistant prostate cancer (2026-06-09),

2. 12472164 - Masitinib for the treatment of sickle cell disease (2025-11-18),

3. 10570122 - Compounds with anti-tumoral activity (2020-02-25),

4. 10392373 - Oxazole derivatives that inhibit Syk (2019-08-27),

5. 10238649 - Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors (2019-03-26),

6. 10202370 - Benzimidazole derivatives as selective proteine kinase inhibitors (2019-02-12),

7. 10092564 - Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation (2018-10-09),

8. 10053455 - Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors (2018-08-21),

9. 10045978 - Treatment of mastocytosis with masitinib (2018-08-14),

10. 9168245 - Selective protein kinase inhibitors (2015-10-27),

11. 9078894 - Treatment of severe persistant asthma with masitinib (2015-07-14),

12. 8993573 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors (2015-03-31),

13. 8962665 - Thiazole and oxazole kinase inhibitors (2015-02-24),

14. 8940894 - Aminothiazole compounds as kinase inhibitors and methods of using the same (2015-01-27),

15. 8906357 - Treatment of multiple sclerosis with masitinib (2014-12-09),

Company Overview

Ab Science is a biopharmaceutical company based in Paris, France, specializing in the development of innovative treatments for serious diseases. The company focuses on the discovery and commercialization of protein kinase inhibitors, which play a crucial role in various therapeutic areas, including oncology and neurodegenerative disorders. Ab Science is committed to advancing scientific research and improving patient outcomes through its cutting-edge technologies and rigorous clinical trials.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

29 Patents

#183 in Paris

#743 in France

#22,570 in the World

Ab Science

Forward Citations = 61

29 inventors:

Alain Moussy (28 out of 28 patents)

Jean-Pierre Kinet (10 out of 15 patents)

Abdellah Benjahad (10 out of 11 patents)

4. Franck Sandrinelli (6 out of 6 patents)

5. Willy Picoul (6 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ab Science. Retrieved from https://idiyas.com/company/ab-science

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…